BackgroundGlomus tumor is a benign and vascular hamartoma that originates from the neuromyoarterial cells of the normal glomus apparatus in the reticular dermis. The etiology of glomus tumors is unknown. It usually presents as a small, slightly raised, bluish or pinkish-red, painful nodule of the fingertips and the pulp. we report an atypical case of a patient of painless glomus tumor.Case presentationOur patient, a 60-year-old Moroccan man, had a 2.5 cm purplish painless soft tumor, covered with melliciric and hemorrhagic crusts, involving the first phalanx of his right index finger. This tumor was compressing his nail plate. No bony lesions were identified by radiographic studies, but magnetic resonance imaging was suggestive of glomus tumor. Surgical excision was performed with directed healing.ConclusionsThe diagnosis of a glomus tumor is an eventuality even in the absence of pain.

BackgroundGlomus tumors are rare, benign, vascular neoplasms arising from the glomus body. Although they can develop in any part of the body, they commonly do so in the upper extremities, most frequently subungual areas. They can be either solitary or multiple. Most typically they present as a small, round, bluish nodule visible through the nail plate with a classic triad of symptoms: hypersensitivity to cold, heightened pinprick sensitivity, and paroxysmal pain. Several tests can help in diagnosing these tumors with multiple imaging tools such as X-ray, magnetic resonance imaging, and ultrasonography. However, only histology can confirm the diagnosis. Complete surgical excision of the tumor is the only effective treatment to achieve pain relief and low recurrence rate.Case presentationWe report here a rare case of a 54-year-old Moroccan Berber woman presenting with a 10-year history of a glomus tumor at an unusual site. Dermoscopy and histology were helpful to confirm the diagnosis.ConclusionsWe aim to discuss clinical, dermoscopical aspects of this tumor and surgical modalities. We also emphasize the importance of keeping this tumor in mind among the possibilities of differential diagnosis of painful digital nodules.

No abstract

No abstract

No abstract

Plexiform neurofibroma is a rare benign tumor of the peripheral tissue cells developed in the perineurium, generally associated with neurofibromatosis type 1 (NF1). These entities consist of multiple, twisted masses that grow along the axis of a large nerve, infiltrating and separating normal nerve fascicles. The diagnosis is essentially pathological and treatment is primarily surgical to avoid malignant degeneration. Giant neurofibromas are very difficult to manage surgically as they are extensively infiltrative and highly vascularized. This report describes a case of an advanced plexiform neurofibroma of the right lower back and pelvic region in a 25-year-old female with neurofibromatosis type 1, discovered in early childhood, with limited normal living due to the severe disfigurement as the result of progression of the disease.

Hidradenoma papilliferum also known as papillary hidradenoma is a benign, slow-growing, asymptomatic, adnexal tumor that primarily affects the anogenital area of adult women. The origin of hidradenoma papilliferum was previously thought to be an apocrine sweat gland; recent studies have suggested that it may derive from the anogenital mammarylike gland. It usually presents as slow-growing, asymptomatic flesh-colored nodule in the anogenital area. Its dermoscopic features are poorly reported in the literature. The nodule is composed of tubules and papillary structures arranged in a frond-like pattern. Treatment of hidradenoma papilliferum consists of complete surgical excision. We report the characteristics of two cases of this rare entity.

Background: Pemphigus is a severe autoimmune blistering disease mediated by pathogenic anti-desmoglein antibodies leading to an inter keratinocyte disjunction. Rituximab is a monoclonal antibody that binds to the CD-20 antigen of B lymphocytes, which causes B-cell depletion and a subsequent reduction in pathogenic autoantibodies. Its therapeutic role in vulgaris and superficial pemphigus has been progressively growing with increasing evidence of successful outcomes. Material and Methods: It was a prospective study extending for two years in the dermatology department of the UHC Hassan II in Fez, dealing with patients with pemphigus who are severe or resistant to conventional treatments treated with Rituximab. We analyzed the efficacy and tolerance of Rituximab in the treatment of severe and refractory forms of our pemphigus population. Results: Patients treated by Rituximab were 13. Eleven cases of pemphigus vulgaris and two cases of superficial pemphigus In our series, Rituximab was used with satisfactory, indeed, 6 patients achieved complete remission, while 4 had partial remission. Side effects of Rituximab were infectious complications. Conclusions: We highlight the efficiency and safety of Rituximab in our series.